-
-
-
7 . Periodical
A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Lenalidomide in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- 저자
- by Burnett, Christine; Gordon, Gary; Strack, Thomas; Lehner, Tara; Higgins, Jack P, et al.
- 소스
- Blood; November 2019, Vol. 134 Issue: Supplement 1 p1597-1597, 1p
-
7 . Periodical
A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara)
- 저자
- by Kumar, Shaji K.; Cornell, Robert F.; Landgren, Ola; Ailawadhi, Sikander; Higgins, Jack P, et al.
- 소스
- Blood; November 2019, Vol. 134 Issue: 1, Number 1 Supplement 1 p1867-1867, 1p